{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'Table 10:', 'Perioperative Schedule of Assessments in Patients Undergoing Operative', 'Procedures', 'Perioperative Evaluation Perioda', 'Dental/Surgical', 'Preoperative', 'Postoperative', 'Postoperative', 'Postoperative', 'Procedure', 'Screening', 'Visit 1', 'Visit 2', 'Visit 3', 'Visit', 'SDay -3 to', 'SDay 0', 'SDay 1b', 'SDay 2 to 14\u00b0', 'SDay 28d', 'SDay -1', 'Directed Physical', 'X', 'X', 'Examination d', 'Vital Sign', 'X', 'X', 'Measurements', 'Clinical Laboratory', 'X', 'xb', 'X', 'X', 'X', 'Assessments\u00b9', 'TG', 'X', 'X8.h', 'Xk', 'Xk', 'Xk', 'AT Activity Level', 'X', 'X\u00b9', 'FVIII/IX Levels8', 'X', 'X8.h', 'Xk', 'XK', 'XK', 'Perioperative', 'X\u00b9', 'X', 'X', 'Questionnaire', 'Completion of', 'Hemostatic', 'X\u00b9', 'X', 'Treatment Coverage', 'Note: Any operative procedure dates (SDay -3 to SDay 28) may overlap with the study Schedule of Assessments (Table 1)', 'Abbreviations: APTT=activated partial thromboplastin time; AT=antithrombin; BPA=bypassing agent; SDay=surgery day;', 'TG=thrombin generation', 'a', 'During the Perioperative Evaluation Period, AEs and concomitant medications will be collected continuously per study', 'Schedule of Assessments (Table 1).', 'b', 'Assessments to be completed within 24 hours (12 hours) from the time of end of the procedure.', 'c Visit may occur anytime between SDay 2 to SDay 14, postoperatively, on a day to be determined by the Investigator. If multiple', 'visits are planned between Days 2-14 after the procedure, the perioperative questionnaire for Postoperative Visit 2 should be', 'completed on the day of the last visit.', 'd', 'Directed physical examination (see Section 7.5.3).', 'e Vital signs will be the same as conducted in the clinical study protocol Schedule of Assessments (Table 1).', 'f', 'Clinical laboratory assessments will include coagulation, hematology, and biochemistry (Table 5).', 'g If factor or BPA administration and the surgical procedure occur at the study center visit, one sample should be collected pre-', 'factor/BPA administration and two samples should be collected post- factor/BPA administration on the day of the procedure.', 'The factor/BPA sample may be collected any time before factor or BPA administration. The post- -factor/BPA samples', 'should optimally be collected at 10 min (=5 min) and 60 min (10 min) after factor or BPA administration. The actual times of', 'collections should be recorded.', 'h', 'If the operative procedure is not performed at a study center, the assessment is recommended.', 'i', 'Not necessary if captured at preoperative screening.', 'j Hemostatic efficacy is to be assessed intraoperatively with the perioperative questionnaire on the day of the procedure (SDay 0);', 'assessment may be completed up to 8 hours postoperatively. The perioperative questionnaire will also be completed at', 'Postoperative Visit 1 and Visit 2. It is recommended that the Investigator complete this assessment in consultation with the', 'surgeon or dentist who performed the operative procedure.', 'k If factor or BPA administration occurs at the study center visit, then assessments should be collected at the following time', 'points: pre-factor/BPA administration; 10 min (=5 min) post-factor/BPA administration; and 60 minutes (=10 min) post-', 'factor/BPA administration. The actual times of collection should be recorded.', '1', 'The date/time of when perioperative hemostatic treatment and thromboprophylaxis (if applicable) coverage was completed will', 'be captured. If completed at Postoperative Visit 2, the date/time of completion should be recorded and the SDay 28 visit is not', 'required.', 'Property of the Sanofi Group - strictly confidential', '79', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', '11.3.', 'International Society on Thrombosis and Hemostasis Guideline for', 'Assessment of Treatment Response', 'ISTH recommendations [10] are provided in the table below for assessment of treatment', 'response (Table 11).', 'Table 11:', 'Assessment of Treatment of Acute Joint/Muscle Bleeding Episodes', 'Category', 'Response', 'Excellent', 'Complete pain relief within 8 hours and/or complete resolution of signs of bleeding', 'after the initial injection and not requiring any further replacement therapy for relief', 'of persistent symptoms and signs in the same joint within 72 hours', 'Good', 'Significant pain relief and/or improvement in signs of bleeding within', 'approximately 8 hours after a single injection, but requiring more than one dose of', 'replacement therapy within 72 hours for complete resolution', 'Moderate', 'Modest pain relief and/or improvement in signs of bleeding within approximately', '8 hours after the initial injection and requiring more than one injection within', '72 hours but without complete resolution', 'None', 'No or minimal improvement, or condition worsens, within approximately 8 hours', 'after the initial injection', '11.4.', 'Bleed Severity Definitions', 'The definitions of bleed severity are shown in Table 12.', 'Table 12', 'Bleed Severity Definitions', 'Bleed Severity', 'Definition', 'Minor', 'Early joint bleeding; mild muscle bleeding; or mild bleeding (any other', 'location)', 'Moderate', 'Definite joint bleeding; moderate muscle bleeding; moderate bleeding', '(any other location); known trauma (other than head trauma or fractures)', 'Major', 'Severe bleeding that is life- or limb-threatening; including fractures and', 'head trauma', '11.5.', 'Country-Specific Requirements', 'Country-specific requirements are provided in separate country-specific protocol.', 'Property of the Sanofi Group - strictly confidential', '80', '(electronic 1.0)']\n\n###\n\n", "completion": "END"}